Bioactivity:

LY2090314, an effective GSK-3_/_ inhibitor (IC50: 1.5 nM/0.9 nM), may improve the efficacy of platinum-based chemotherapy regimens. LY2090314 has been used in trials studying the treatment of Leukemia, Advanced Cancer, and Pancreatic Cancer.

CAS nr:

603288-22-8

Purity:

98%

Molecular Weight:

512,53

SMILES:

N1(C(=O)N2CCCCC2)Cc2cc(cc3c(C4=C(c5cnc6n5cccc6)C(=O)NC4=O)cn(CC1)c23)F

Formula:

C28H25FN6O3

Pathway:

Stem Cells,PI3K/Akt/mTOR signaling

Target:

GSK-3,GSK-3